Mostrando 10 resultados de: 29
Publisher
Journal of Nanobiotechnology(4)
Pharmaceutics(3)
Biomedicine and Pharmacotherapy(2)
Journal of Alzheimer's Disease(2)
Applied Sciences (Switzerland)(1)
Área temáticas
Enfermedades(23)
Farmacología y terapéutica(22)
Medicina y salud(12)
Fisiología humana(8)
Ginecología, obstetricia, pediatría, geriatría(3)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(29)
ODS 9: Industria, innovación e infraestructura(20)
ODS 2: Hambre cero(5)
ODS 12: Producción y consumo responsables(1)
ODS 17: Alianzas para lograr los objetivos(1)
Origen
scopus(29)
ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker
ReviewAbstract: Alzheimer's disease (AD) represents a global burden in the economics of healthcare systems. Amyloid-Palabras claves:ADAM10, Alzheimer's disease, Natural compounds, Pharmaceutical, α-SecretaseAutores:Antoni Camins, Busquets O., Cano A., Cominetti M.R., Di Luca M., Endres K., Ettcheto M., Manzine P.R., Marcello E., Olloquequi J., Pelucchi S.Fuentes:scopusBenzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia
ArticleAbstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to theirPalabras claves:Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORSAutores:Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer's disease mice model
ArticleAbstract: Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its iPalabras claves:Alzheimer's disease, APP/PS1 mice, EGCG, Epigallocatechin gallate, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Barroso E., Cano A., Chang J.H., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Souto E.M.B., Turowski P.Fuentes:scopusDevelopment and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment
ArticleAbstract: Riluzole-loaded PLGA nanoparticles (RLZ-NPs) were developed to improve the biopharmaceutical profilePalabras claves:Gellan gum, glaucoma, In situ gelling gel, PLGA nanoparticles, riluzoleAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García-Torra V., Halbaut L., Luisa García M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusExtracellular vesicles, the emerging mirrors of brain physiopathology
ArticleAbstract: Extracellular vesicles are secreted by a wide variety of cells, and their primary functions includePalabras claves:Alzheimer’s disease, exosomes, Extracellular vesicles, Glioblastoma, multiple sclerosis, amyotrophic lateral sclerosis, neurodegenerative diseases, Parkinson’s DiseaseAutores:Antoni Camins, Bernuz M., Boada M., Cano A., de Antonio E.E., Ettcheto M., Martí M., Pividori M.I., Puerta R., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice
ArticleAbstract: Aim: To compare free and nanoparticle (NP)-encapsulated epigallocatechin-3-gallate (EGCG) for the trPalabras claves:3-nitropropionic acid, Epigallocatechin-3-gallate, Huntington's disease, neurodegenerative diseases, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Kühne B.A., Sanchez-Lopez E., Souto E.M.B., Turowski P.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusExosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
ReviewAbstract: Neurodegenerative diseases constitute a group of pathologies whose etiology remains unknown in manyPalabras claves:exosomes, Extracellular vesicles, Nanomedicine, nanotechnology, neurodegenerative diseasesAutores:Antoni Camins, Boada M., Cano A., Ettcheto M., Muñoz-Morales Á., Ruíz A., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopus